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THE capacity to down-regulate the production of
IL-8 by LPS-activated human polymorphonuclear
cells (PMN) has been demonstrated for IL-4, IL-10,
and TGF. We compared their relative capacities
and further extended this property to IL-13. We
report a great heterogeneity among individuals
related to the responsiveness of PMN to the IL-4
and IL-13 inhibitory effects while their response
to the IL-10 effect was homogenous. The inhibi-
tory activities were observed at the transcrip-
tional level. IL-8 induction by TNFz was, unlike its
induction by LPS, resistant to the inhibitory
effects of IL-IO, IL-4, IL-13 and TGF. Further-
more, IL-10 and IL-4 inhibitory activity were less
effective when TNFz was acting synergistically
with LPS to induce IL-8 production by PMN. LPS-
induced cell-associated IL-8, detected in the PMN
cultures, could be marginally inhibited by IL-4
and IL-10. Altogether, our data demonstrate that
IL-13 is able to inhibit LPS-induced IL-8 produc-
tion by human PMN, although IL-IO remains the
most active anti-inflammatory cytokine. Despite
the capacity of IL-4, IL-IO, and IL-13 to limit the
production of TNFz-induced IL-8 in a whole blood
assay, none was able to inhibit this production
when studying isolated human polymorphonuc-
lear cells.
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Introduction
Inflammation is characterized by a complex
interaction of pro- and anti-inflammatory media-
tors. A favourable balance leads to a recovery of
homeostasis while an unfavourable balance,
associated with an exacerbated release of pro-
inflammatory cytokines, leads to deleterious
effects. Individual background seems to govern
this equilibrium. In man, for example, it is
known that a great heterogeneity exists be-
tween individuals in terms of their levels of
production of TNFcz by LPS-stimulated mono-
cytes. Similarly, the capacity to produce the
Th2 cytokines, including the anti-inflammatory
IL-4 and IL-IO cytokines, rather than the Thl-
derived cytokines which include the pro-inflam-
matory interferonq,, seems to be genetically
determined.
2 Furthermore, the sensitivity of
target cells to cytokine signals constitutes an-
other 3 level of heterogeneity. The capacity of IL-
4, IL-1O, IL-13 and TGF to inhibit the synthesis
of pro-inflammatory cytokines by activated
monoces/macrophages has been well estab-
4 7 lished.- However, the mononuclear phago-
cytes are not the unique source of IL-1, TNFcz,
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IL-6 and IL-8, and many other cell types can
contribute to the inflammatory process as a
consequence of their ability to produce pro-
inflammatory cytokines. Upon activation, poly-
morphonuclear cells (PMN) are a major source
of mediators, including eicosanoids, proteolytic
enzymes and free radicals, all of which contri-
bute to the exacerbation of inflammatory pro-
cesses. In vivo models of infection have clearly
established that PMNs do contribute to tissue
injury and organ dysfunction and are involved
in the development of fatal complication in
sepsis syndrome.
8-1 Their capacity to be acti-
vated by cytokines following the release of
bacterial derived substances has been illustrated
in in vivo models of neutrophil depletion.11’12
Indeed, many substances, including opsonized
yeast, bacterial-derived productsusuch as en-
dotoxin (LPS, lipopolysaccharide)mand cyt0-
kinesmsuch as IL-1, IL-2 and TNFzmare able to
triggerMN, leading to a notable production of
IL-8.13- IL-8, being a potent chemokine and
activator of PMN, has emerged in recent years
as a pivotal factor of inflammation. The pre-
sence of IL-8 in vivo has been clearly associated
7 19 with neutrophil recruitment and the sever-
(C) 1996 Rapid Science PublishersDown-regulation ofPMN-derived IL-8
ity of the pathology.
2-28 Indeed, levels of IL-8 Denmark), at 37C in a 5% CO2 incubator for
in broncho-alveolar lavage fluids and in plasma 18-24 h.
of septic patients correlate with the clinical PMN (2 106 cells/ml) were cultured in
outcome.23-28 In addition, experiments using RPMI-1640 medium supplemented with L-gluta-
anti-IL-8 antibodies have clearly demonstrated mine, antibiotics and 5% heat inactivated nor-
the contribution of IL-8 in the inflammatory mal human serum (a pool of sera from healthy
process.29-31 In the present study we have volunteers). 0.5 ml per well in 24-well multidish
compared the relative capacities of IL-4, IL-IO, plates of PMN suspension were incubated for
IL-13 and TGF to interfere with IL-8 produc- 18-24 h at 37C in a 5% CO2 incubator. The
tion by activated human PMN. This is the first cell viability after 24 h ranged from 64% to 84%.
report on the individual heterogeneity related Stimuli were added at the beginning of the
to the inhibitory activities of IL-4 and IL-13. In culture in a volume not exceeding 10 >1. At the
addition, we demonstrated that these cytokines end of the culture, the supernatants were
are devoid of any activity when TNF was harvested, centrifuged 10 min at 300g and
employed as the triggering agent, and showed 15C and kept at -20C before cytokine assess-
that the inhibitory activity of IL-IO on LPS- ments. In some experiments, at the end of the
induced IL-8 was significantly hampered by the culture period, the cells were lysed by adding
presence of TNFa. 100 1 of lysis buffer to the cell pellet (TRAx(R)
buffer, T-Cell Diagnostic, USA) before adding
100 bl of diluent buffer (TRAx(R) buffer, T-Cell
Material and Methods Diagnostic, USA) and 300 bl of RPMI medium.
Human polymorphonuclear cells
Reagents Blood was drawn from human volunteers
(Fondation Nationale de Transfusion Sanguine, Escherichia coli (Olll:B4) lipopolysaccharide
Paris) on heparin (20 IU/ml). Ten volumes of was purchased from Sigma (USA). Recombinant
blood were mixed with 2 volumes of glucose human IL-IO (1-2 10r U/mg) and IL-13 were
dextran (3% glucose; 3% dextran T250 Pharma- a generous gift of Dr John Abrams (DNAX, Palo
cia, Sweden), and the leukocytes recovered Alto, USA) and Dr Adrian Minty (Sanofi Re-
following a 40 min sedimentation at room tem- cherche, Labege, France), respectively. Similar
perature. Leukocytes were then diluted 1:2 in results have been obtained with IL-IO and IL-13
RPMI-1640 medium and layered on Ficoll-Hypa- from R&D Systems (USA). TNF(, was obtained
que (Milieu de Sparation des Lymphocytes, from Rh6ne Poulenc (France) and IL-4 and
MSL, Eurobio, Les Ulis, France). The ratio was 2 TGFI3 (2 107 U/mg) were purchased from
volumes of leukocytes to 1 volume of MSL. After Immugenex (USA) and R&D systems (USA),
centrifugation for 25 min at 15C and 500 g, respectively.
the pellet was washed and centrifuged once
5 min at 300 g. Contaminating erythrocytes Ik-8 ELISA were lysed following a 5 min incubation at 4C of
the cell pellet resuspended in 5 ml of lysis IL-8 ELISA was performed as previously
buffer (NH4C1- 8.32 g/l; NaHCO- 0.84 g/l; described
28 using a monoclonal anti-human IL-8
Na4EDTA 43.2 mg/1). Lysis was stopped by antibody and a rabbit polyclonal anti-IL-8 anti-
adding a large excess of RPMI and the cells body kindly provided by N. Vita (Sanofi Re-
washed and centrifuged for 10 min at 200 g. cherche, Labge, France).
The viability of polymorphonuclear cells (PMN)
was assessed by numerating the cells in 0.1% Northern blot analysis
cosine. A non-specific esterase staining was
performed to evaluate the monocyte contamina- Total cellular RNA from 20-30 106 PMN was
tionwhich never exceeded 0.5%. extracted using the guanidine isothiocyanate
method.32 5-10g total RNA per wells were
separated on 1% agarose gels containing 6.6% In vitro culture formaldehyde, transferred to Hybond-N+ mem-
For whole blood assays, blood was diluted 1:5 branes (Amersham) and hybridized with 32p_
in RPMI-1640 medium (Bio-Whittaker, USA) labelled IL-8 and -actin probes. The human IL-8
supplemented with L-glutamine (300 mg/1) and cDNA probe, generously provided by Dr J.
antibiotics (penicillin, 100 IU/ml; streptomycin, Oppenheim (NCI, Frederick, MD), was a pur-
100 pg/ml), and 0.5 ml cultured per well in ified 0.5 kb EcoR I fragment. The mouse [3-actin
24-well multidish plates (Nunclon, Rockville, cDNA probe was a 0.97kb PSTI fragment.
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Membranes were washed and exposed to X-ray
films (Kodak XAR-5) for 24-48 h at -70C in
the presence of an intensifying screen. Relative
signal strength was measured by laser densito-
metry (Ultroscan XL, Pharmacia). The ratio IL-8:
-actin mRNA was then calculated.
Statistical analysis
Results are expressed as mean 4- SEM. Statistical
analysis was performed using the Wilcoxon
signed-rank test.
Results
Inhibition of IL-8 production by IL-13
compared with other anti-
inflammatory cytokines
As shown in Fig. 1A, IL-4, IL-IO, and IL-13 are
able to inhibit in a dose-dependent fashion the
IL-8 production in a whole blood assay triggered
by LPS. The results are the mean of experiments
performed with five different donors and were
homogeneous. This was not the case when
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FIG. 1. (A) Dose-response curve of the inhibitory effects of
IL-4, IL-10 and IL-13 on IL-8 production in a whole blood
assay. Cells were stimulated by 100 ng/ml Escherichia coil
LPS. The data are the mean +/- SEM of five different experi-
ments. (B) Dose-response curve of the inhibitory effects of
IL-4, IL-10, IL-13 and TGFI on IL-8 production by LPS
activated PMN. Cells from one donor for whom IL-4 and IL-
13 had inhibitory activity were activated by 100 ng/ml E. coil
LPS.
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these cytokines were studied with isolated hu-
man polymorphonuclear cells (see below, the
individual responsiveness). A dose-response
curve of the inhibitory effect of IL-4, IL-10 and
IL-13 on LPS-induced IL-8 production by acti-
vated human PMN from one given donor is
shown in Fig. lB. IL-IO, IL-4 and IL-13 were
able, in a dose-dependent fashion, to inhibit the
release of IL-8 by LPS-activated PMN. In the
whole blood assay as well as with the isolated
PMN, no further inhibitory effects could be
obtained with 30 ng/ml of cytokines, compared
with 10 ng/ml, and subsequently, a fixed cyt0-
kine concentration of 10 ng/ml was used.
Neither IL-IO nor IL-13 had any effect on the
’spontaneous’ IL-8 production by human PMN
(262 -t- 64 pg/ml and 240 4- 41 pg/ml, respec-
tively vs 191 4- 39 pg/ml; n 12). IL-4 had a
weak but significant capacity to limit the spon-
taneous production of IL-8 (103 4- 20 pg/ml;
p < 0.01) while TGF amplify it (588 + 234 pg/
ml; p 0.05).
Inhibitory activities of IL-IO, IL-4, IL-13 and
TGF were compared on PMN activated by
either LPS or TNF(z. As shown in Fig. 2A, the
studies on the inhibition of LPS-induced Ib8
production performed with the cells from differ-
ent donors, revealed that IL-IO at 10 ng/ml was
very efficient whereas similar amounts of Ib4
were less active (81% inhibition vs 37% inhibi-
tion; p < 0.01). IL-13 and TGF, with respec-
tively 16% and 12% inhibition, were very
weakly inhibitory, although this was statistically
significant in view of the large number of
experiments performed (n 12).
When TNF(z was employed as the stimulating
agent, IL-IO had a high inhibitory activity, and
IL-4 and IL-13 had similar capacity to counteract
the production of IL-8 by whole blood cells,
while TGF was devoid of any inhibitory
activity (data not shown). In contrast to the
results obtained in whole blood assays, none of
the anti-inflammatory cytokines were able to
counteract the IL-8 production induced by
TNF0t (Fig. 2B).
Synergy between LPS and TNF: effect
of anti-inflammatory cytokines
Since cells are most likely exposed to many
triggering signals during infection by Gram
negative bacteria, it was interesting to investi-
gate the capacity of the anti-inflammatory cyto-
kines to reduce the IL-8 production stimulated
by both LPS and TNF(z. The results are shown
in Fig. 2C. The activation of whole blood cells
by both LPS and TNFez led to additive Ib8
production (data not shown), while a synergyDown-regulation ofPMN-derived IL-8
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FIG. 2. Comparative inhibitory activities of the same con-
centration (10 ng/ml) of IL-10, IL-4, IL-13 and TGFI3 on LPS-
induced (100ng/ml) (A), TNFc-induced (10ng/ml) (B), and
on the combination of 100 ng/ml Escherichia coil LPS and
10 ng/ml TNFc-induced (C)IL-8 production by human PMN.
The results are expressed as the mean 4- SEM of 12 (A), 8
(B), and 10 (C) different experiments (* p < 0.05; ** p < 0.01
vs LPS alone, TNF alone or LPS + TNF).
was noticed when PMN were studied (arith-
metic sum 5007 4- 514 pg/ml vs experimental
data 6225 -+- 651 pg/ml, n 17, p < 0.02). In
whole blood cells, IL-10 and IL-4 were particu-
larly efficient in inhibiting IL-8 production (data
not shown). On the contrary with PMN, only IL-
10 dramatically inhibited IL-8 production, while
IL-4 was weakly inhibitory, and IL-13 and TGF
were not significantly inhibitory. However, the
inhibitory activity of IL-IO, which was higher
than 80% when LPS was used alone, dropped to
only 45% (for the same concentration of 10 ng/
ml) when both activators were employed.
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FIG. 3. Comparative inhibitory activities for individual do-
nors of the same concentration (10 ng/ml) of IL-10, IL-4, IL-
13 on IL-8 production by human PMN stimulated by 100 ng/
ml Escherichia coil LPS. Results are expressed as percentage
of inhibition and each symbol represents a separate donor.
induced inhibition varied considerably between
donors. A weak, but significant correlation
exists between the potency of IL-4 and IL-13 to
inhibit the IL-8 production by LPS-stimulated
PMN (r 0.52, p < 0.05).
Detection of cell-associated IL-8
When cell-associated IL-8 was assessed, high
concentrations of this cytoMne could be de-
tected in the PMN lysates obtained with the
TRAx(R) buffer, independently of the triggering
signal (Table 1). To further evaluate the propor-
tion of the cytokine linked to its receptor on
PMN, IL-8 was measured following treatment of
cells with a glycine-HC1 buffer. One-fifth of the
cell-associated IL-8 was recovered with such a
treatment (data not shown).
IL-4, IL-10 and IL-13 but not TGF could also
reduce the presence of cell-associated IL-8 in
the PMN cultures (Table 2). However, the
reduction was less pronounced than when
studying released IL-8 and did not reach statis-
tical significance.
Inhibition of IL-8 mRNA accumulation
induced by LPS
To determine whether the anti-inflammatory
cytokines act at the transcriptional level, North-
ern blot analysis of IL-8 mRNA were performed
Individual responsiveness
When the results were individually plotted (Fig.
3), it was noticed that the inhibitory effect of IL-
10 was very similar between donors (range:
from 65% to 90% inhibition) whilst the effect of
IL-4 varied greatly depending on donor (range:
from 0% to 78% inhibition). Similarly, IL-13-
Table 1. Released and cell-associated IL-8 (pg/ml) induced
by LPS and TNF(z in neutrophil cultures (n 5)
Inducers Released IL-8 Cell-associated IL-8
None 275 -I- 61 635 -t- 716
LPS Escherichia coli 6010 + 261 8455 + 2 163
(100 ng/ml)
TNF(z (10 ng/ml) 417 4- 431 3967 4- 213
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Table 2. Effects of IL-4, IL-10, IL-13 and TGFI on released
and cell-associated IL-8 (pg/ml) production induced by LPS
in neutrophil cultures
Addition to the culture Released IL-8 Cell-associated IL-8
None 335 +/- 46 266 +/- 266
LPS Escherichia coil 8120 +/- 839 9 340 +/- 2 762
(100 ng/ml)
LPS +/- IL-4 (10 ng/ml) 3394 +/- 787 5455 +/- 592
LPS -I- IL-10 (10 ng/ml) 2 732 +/- 223 4870 +/- 078
LPS +/- IL-13 (10 ng/ml) 4408 +/- 652 7 499 +/- 2850
LPS -I- TGFI (10 ng/ml) 6026 +/- 227 9344 +/- 3661
aMean -t- SEM of five different experiments.
t=5h
28 S
18S IL-8
on total RNA isolated from PMN incubated for
5 h in the presence of LPS alone or LPS plus
anti-inflammatory cytokines. No further signifi-
cant effects could be observed at earlier time
(data not shown). As shown in Fig. 4A, LPS
alone or LPS + TGFf3 led to an accumulation of
IL-8 mRNA. No such accumulation was ob-
served upon the addition of IL-10, IL-4 and IL-
13. When analysing the experiments performed
with five different donors, a statistically signifi-
cant effect of IL-IO and IL-4 was noticed
(p 0.04), while a trend was observed with IL-
l3 (p 0.08). The effect of IL-13 was observed
in four out of five different experiments in
agreement with the individual heterogeneity as
assessed at the protein level.
Discussion
The intensity of the inflammatory response is
the result of a complex balance between pro-
and anti-inflammatory mediators. Among the set
of cytokines, IL-1, IFN/, and TNF( orchestrate
the inflammatory process, whilst IL-4, IL-10, IL-
13, and TGFI3 have been characterized as anti-
inflammatory agents. This latter group is able to
reduce the production of the pro-inflammatory
4 7 cytokines by monocytes/macrophages- and
also to interfere with some of their activities. In
the present study we have compared the
capacity of these anti-inflammatory cytokines to
inhibit the production of IL-8 by isolated poly-
morphonuclear cells stimulated by LPS and/or
TNFc. Human polymorphonuclear cells, the
main target cells for IL-8, can be activated to
release IL-8 following stimulation by LPS and/or
TNFc. These results suggest that, following
their recruitment in inflammatory tissues and
local activation by bacterial-derived products or
cytokines, PMN can perpetuate the chemo-
attractant process and cellular activation.
We observed that the production of IL-8 by
LPS-activated human polymorphonuclear cells
could be down-regulated by IL-IO, IL-4, IL-13
and to a lesser extent by TGF. This is in
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FIG. 4. (A) Northern blot analysis of IL-8 and I-actin mRNA
expression in LPS- (100 ng/ml) activated human PMN in the
absence or presence of anti-inflammatory cytokines (10 ng/
ml). Both IL-8 and I-actin mRNA were quantified by laser
densitometry; the IL-8; I-actin ratios were 0.05 for control
(0), 0.89 for LPS, 0.25 for LPS +/- IL-4, 0.34 for LPS + IL-10,
0.33 for LPS +/- IL-13, and 0.89 for LPS -t- TGFI. (B) Means of
IL-8: I-actin ratios of five experiments performed with PMN
from different donors (inset: individual results for the
experiments performed with LPS and LPS + IL-13)
(+ p < 0.05 vs LPS).
agreement with the results of Kasama et al.33
and Cassatella et al.,34 who reported the capa-
city of IL-10 to limit IL-8 production, and with
those of Wertheim et al.35 who obtained similar
results with IL-4. We observed that IL-4 was less
efficient than IL-10 in agreement with the
report of Wang et +t. In addition, when
comparing the efficiency of the various anti-
inflammatory cytokines, we have clearly shown
a profound variability of PMN sensitivity to IL-4
and IL-13 between individuals. In contrast, Ibl0
was uniformly active. These results probably do
not reflect differences at the IL-4 receptor levels
since there was no correlation between the
levels of IL-8 and IL-lra released in response toDown-regulation ofPMN-derived IL-8
LPS plus IL-4.7 In preliminary experiments, it
seemed that the individual responsiveness to IL-
4 might vary with time since the percentage of
inhibition was not reproducible with the cells
prepared from the same donor at different time
intervals. Although IL-13 shares many activities
with IL-4, in most experiments IL-13 appeared
less active than IL-4. The observed inhibitory
activity was also observed at the transcriptional
level. In a recent report, Girard et al.8 showed
that IL-13 itself could induce IL-8 production by
human PMN. We never observed such induction
at the protein level (n 12 different donors).
We are unable to explain such discrepancy, the
only differences noted being the origin of the
recombinant cytokines and the culture condi-
tions. Further experiments should be performed
to address this issue.
The up- and down-regulation of TNF-in-
duced IL-8 production by PMN has been rarely
studied.34 Interestingly, none of the tested anti-
inflammatory cytokines were able to inhibit the
production of IL-8 by PMN when TNFc was
used as the stimulus. This observation seems to
be linked to an intrinsic property of PMN since
IL-10, IL-4 and IL-13 were able to significantly
inhibit the IL-8 production by whole blood cells
activated by TNFcz (data not shown). However,
IL-4 and IL-IO can modulate some PMN func-
tions when activated by TNFcz. Indeed, we have
previously shown that IL-lra production by
TNFcz-activated PMN could be up-regulated by
these cytokines.
37 As shown in Table 3, the
down-regulation of IL-8 production by PMN by
the so-called anti-inflammatory cytokines, as
well as the up-regulation of IL-lra production is
dependent on the nature of the triggering signal
and these modulations are not correlated. Thus,
the modulation of the cytokine production by
IL-4, IL-IO or IL-13 is dependent on the nature
of the stimuli. In addition, the nature of the
activated cells play a crucial role as illustrated
by the fact that IL-4 and IL-10 which are well
Table 3. Effect of IL-4, IL-10, IL-13 and TGFI on the produc-
tion of IL-8 and IL-lra by polymorphonuclear cells activated
by either LPS or TNFc
PMN Produced
activators cytoki nes
Anti-inflammatory cytokines
IL-4 IL-10 IL-13 TGFI3
LPS IL-8 $$c $,1,$
IL-lrab 1"1" 0
TNF IL-8 0 0
IL-lrab 1"1" 1"1"
aThe present studY.37 bMarie et aL (1996).
c$, or 0 indicate reduction, enhancement, or absence of significant
effect on cytokine production. The number of arrows is related to
the intensity of the phenomenon.
known to inhibit the LPS-induced IL-8 produc-
tion by monocytes-macrophages,4-7 enhance it
when acting on endothelial cells.39
We have also investigated the simultaneous
action of LPS andTNFc on IL-8 production,
particularly since PMN in infectious sites may
well be exposed to both agents. In these
experimental conditions, only IL-10 retained its
ability to inhibit the IL-8 production by acti-
vated PMN, whereas IL-4 was far less active and
IL-13 had no more inhibitory activity. However
the inhibitory effect of IL-IO was far less
pronounced than when LPS was used alone as a
stimulus (48-58% vs 83% inhibition).
A significant amount of cell-associated IL-8
was also observed in the PMN culture, which
regularly exceeded that found in the super-
natants. The presence of IL-8 in lysates of
activated PMN might be explained by the
presence of receptor-bound IL-8 and by the
presence of IL-8 in the intracellular compart-
ments, resulting from secretory mechanisms
and/or following the rapid internalization of the
cytokine bound to its receptors.
4 As shown by
Kuhns and Gallin, the accumulation of IL-8
within PMN is localized to a subcellular fraction
of heterogenous light membranous organelles.
41
In addition, the authors suggested that IL-8
accumulation was under translational control.
The fact that the anti-inflammatory cytokines
had a minor effect on the cell-associated form of
IL-8 suggests that most of its detection corres-
ponds to the rapid internalization of surround-
ing IL-8 which is still present in the culture
medium, independently of the presence of IL-4,
IL-IO or IL-13.
In conclusion this is the first report on the
ability of IL-13 to down-modulate the produc-
tion of IL-8 by LPS-activated PMN in comparison
with the other anti-inflammatory cytokines. In
addition, we showed an individual responsive-
ness to the inhibitory activity of IL-4 and IL-13
on IL-8 production by LPS-activated PMN,
whereas IL-10 was uniformly active. It appeared
that IL-IO was the most active cytokine when
LPS was employed as the stimulating agent,
while its inhibitory property could not be
observed when TNFcz was the activator and was
minimized when TNFc was used together with
LPS. This late observation may well be relevant
to some in vivo situations where recruited
PMN encountered in situ various stimulating
signals.
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